Showing results (101-110 of 142) with videos related to
Sort By:
Pageof 15
Blood Advances|February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized TrialShai Shimony, H Moses Murdock, Julia H Keating, et al.British Journal of Haematology|December 17, 2013
Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemiaSantosh L Saraf, Xu Zhang, Tamir Kanias, et al.The Lancet. Oncology|April 6, 2015
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker studyMark Roschewski, Kieron Dunleavy, Stefania Pittaluga, et al.The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK studyShirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyAndrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.Cancer|May 15, 2023
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysisJames M Foran, Zhuoxin Sun, Catherine Lai, et al.JCO Oncology Practice|June 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Hope S Rugo, Mina S Sedrak, et al.Transplantation and Cellular Therapy|November 1, 2023
Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell TransplantationLacey S Williams, Kirsten M Williams, Nancy Gillis, et al.Pageof 15